Table of Content

1. Key Insights

2. Hypofibrinogenemia: Epidemiology Overview at a Glance
2.1. Patient Share (%) Distribution of Hypofibrinogenemia in 2017
2.2. Patient Share (%) Distribution of Hypofibrinogenemia in 2030

3. Executive summary

4. Organizations

5. Disease Overview: Hypofibrinogenemia
5.1. Introduction
5.2. Classification
5.3. Signs and Symptoms
5.4. Pathogenesis
5.5. Diagnosis
5.5.1. Differential Diagnosis
5.5.2. Prenatal Diagnosis

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. 7MM Total cases of Hypofibrinogenemia

7. Country Wise-Epidemiology of Hypofibrinogenemia
7.1. Assumptions and Rationale
7.2. KOL Views: Epidemiology
7.3. United States
7.3.1. Total Cases of Hypofibrinogenemia in the United States
7.3.2. Type-Specific Cases of Hypofibrinogenemia in the US
7.3.3. Acquired Hypofibrinogenemia cases in the US
7.4. Germany
7.4.1. Total Cases of Hypofibrinogenemia in Germany
7.4.2. Type-Specific Cases of Hypofibrinogenemia in Germany
7.4.3. Acquired Hypofibrinogenemia cases in Germany
7.5. France
7.5.1. Total Cases of Hypofibrinogenemia in France
7.5.2. Type-Specific Cases of Hypofibrinogenemia in France
7.5.3. Acquired Hypofibrinogenemia cases in France
7.6. Italy
7.6.1. Total Cases of Hypofibrinogenemia in Italy
7.6.2. Type-Specific Cases of Hypofibrinogenemia in Italy
7.6.3. Acquired Hypofibrinogenemia cases in Italy
7.7. Spain
7.7.1. Total Cases of Hypofibrinogenemia in Spain
7.7.2. Type-Specific Cases of Hypofibrinogenemia in Spain
7.7.3. Acquired Hypofibrinogenemia cases in the Spain
7.8. United Kingdom
7.8.1. Total Cases of Hypofibrinogenemia in the UK
7.8.2. Type-Specific Cases of Hypofibrinogenemia in the UK
7.8.3. Acquired Hypofibrinogenemia cases in the UK
7.9. Japan
7.9.1. Total Cases of Hypofibrinogenemia in Japan
7.9.2. Type-Specific Cases of Hypofibrinogenemia in Japan
7.9.3. Acquired Hypofibrinogenemia cases in Japan

8. Current Treatment Practices

9. Unmet needs

10. SWOT Analysis

11. Bibliography

12. Appendix
12.1. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

15. About DelveInsight



List of Figures


Figure 1: Total Cases of Hypofibrinogenemia in 7MM (2017–2030)
Figure 2: Total Cases of Hypofibrinogenemia in the United States (2017–2030)
Figure 3: Type-specific Cases of Hypofibrinogenemia in the US (2017–2030)
Figure 4: Acquired Hypofibrinogenemia cases in the US (2017–2030)
Figure 5: Total Cases of Hypofibrinogenemia in Germany (2017–2030)
Figure 6: Type-specific Cases of Hypofibrinogenemia in Germany (2017–2030)
Figure 7: Acquired Hypofibrinogenemia cases in Germany (2017–2030)
Figure 8: Total Cases of Hypofibrinogenemia in France (2017–2030)
Figure 9: Type-specific Cases of Hypofibrinogenemia in France (2017–2030)
Figure 10: Acquired Hypofibrinogenemia cases in France (2017–2030)
Figure 11: Total Cases of Hypofibrinogenemia in Italy (2017–2030)
Figure 12: Type-specific Cases of Hypofibrinogenemia in Italy (2017–2030)
Figure 13: Acquired Hypofibrinogenemia cases in Italy (2017–2030)
Figure 14: Total Cases of Hypofibrinogenemia in Spain (2017–2030)
Figure 15: Type-specific Diagnosed Prevalent Cases of Hypofibrinogenemia in Spain (2017–2030)
Figure 16: Acquired Hypofibrinogenemia cases in Spain (2017–2030)
Figure 17: Total Cases of Hypofibrinogenemia in the UK (2017–2030)
Figure 18: Type-specific Cases of Hypofibrinogenemia in the UK (2017–2030)
Figure 19: Acquired Hypofibrinogenemia cases in the UK (2017–2030)
Figure 20: Total Cases of Hypofibrinogenemia in Japan (2017–2030)
Figure 21: Type-specific Cases of Hypofibrinogenemia in Japan (2017–2030)
Figure 22: Acquired Hypofibrinogenemia cases in Japan (2017–2030)


List of Tables


Table 1: Causes of Acquired Hypofibrinogenemia
Table 2: Classification of Hypofibrinogenemia based on levels of functional fibrinogen
Figure 3: Schematic structure of the fibrinogen molecule
Figure 4: Schematic structure of the fibrinogen molecule
Figure 5: Schematic conversion of fibrinogen molecule to active fibrin
Table 6: Common mutations associated with hypofibrinogenemia
Table 7: Hypofibrinogenemia Mutations associated with liver damage
Table 8: Laboratory Assays in congenital fibrinogen deficiencies
Table 9: Laboratory diagnosis results for hypofibrinogenemia.
Table 10: Total cases of Hypofibrinogenemia in USD Million (2017–2030)
Table 11: Total Cases of Hypofibrinogenemia in the US (2017–2030)
Table 12: Type-specific Cases of Hypofibrinogenemia in the US (2017–2030)
Table 13: Acquired Hypofibrinogenemia cases in the US (2017–2030)
Table 14: Total Cases of Hypofibrinogenemia in Germany (2017–2030)
Table 15: Type-specific Cases of Hypofibrinogenemia in Germany (2017–2030)
Table 16: Acquired Hypofibrinogenemia cases in Germany (2017–2030)
Table 17: Total Cases of Hypofibrinogenemia in France (2017–2030)
Table 18: Type-specific Cases of Hypofibrinogenemia in France (2017–2030)
Table 19: Acquired Hypofibrinogenemia cases in France (2017–2030)
Table 20: Total Cases of Hypofibrinogenemia in Italy (2017–2030)
Table 21: Type-specific Cases of Hypofibrinogenemia in Italy (2017–2030)
Table 22: Acquired Hypofibrinogenemia cases in Italy (2017–2030)
Table 23: Total Cases of Hypofibrinogenemia in Spain (2017–2030)
Table 24: Type-specific Cases of Hypofibrinogenemia in Spain (2017–2030)
Table 25: Acquired Hypofibrinogenemia cases in Spain (2017–2030)
Table 26: Total Cases of Hypofibrinogenemia in the UK (2017–2030)
Table 27: Type-specific Cases of Hypofibrinogenemia in the UK (2017–2030)
Table 28: Acquired Hypofibrinogenemia cases in the UK (2017–2030)
Table 29: Total Cases of Hypofibrinogenemia in Japan (2017–2030)
Table 30: Type-specific Cases of Hypofibrinogenemia in Japan (2017–2030)
Table 31: Acquired Hypofibrinogenemia cases in Japan (2017–2030)